Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.43 |
| ▸ | ADH1B | P00325 | 1/20 | 0.43 |
| ▸ | ADH1C | P00326 | 1/20 | 0.43 |
| ▸ | ADH1A | P07327 | 1/20 | 0.43 |
| ▸ | ADH7 | P40394 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11360130 | 0.79 | IDO1 (0.52) | IDO1MEN1KMT2ATHRBTDP1 | |
| SCHEMBL109301 | 0.75 | CYP3A4 (0.52) | IDO1MEN1KMT2ATHRBTDP1 | |
| SCHEMBL29875311 | 0.75 | IDO1 (0.48) | IDO1MEN1KMT2ATHRBTDP1 | |
| SCHEMBL8075682 | 0.75 | IDO1 (0.54) | IDO1MEN1KMT2ATHRBTDP1 | |
| SCHEMBL21034357 | 0.75 | IDO1 (0.48) | IDO1MEN1KMT2ATHRBTDP1 | |
| SCHEMBL21900829 | 0.75 | CYP3A4 (0.46) | IDO1MEN1KMT2ATHRBTDP1 | |
| SCHEMBL5790558 | 0.73 | IDO1 (0.46) | IDO1MEN1KMT2ATHRBTDP1 | |
| SCHEMBL28672152 | 0.73 | IDO1 (0.46) | IDO1MEN1KMT2ATHRBTDP1 | |
| Hydrochloric Acid SCHEMBL10435079 | 0.73 | MAPT (0.56) | IDO1MEN1KMT2ATHRBTDP1 | |
| SCHEMBL570594 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7303760-B2 | Method for treating multi-drug resistant tumors | ALZA CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-7276248-B2 | Conjugate having a cleavable linkage for use in a liposome | ALZA CORPORATION (US) | 2007-10-02 | — | — | US | disclosed |
| EP-1617873-A2 | MITOMYCIN CONJUGATES CLEAVABLE BY THIOLS | Alza Corporation (US) | 2006-01-25 | — | — | EP | disclosed |
| US-6984396-B2 | Conjugate having a cleavable linkage for use in a liposome | ALZA CORPORATION (US) | 2006-01-10 | — | — | US | disclosed |
| US-20050271715-A1 | Conjugate having a cleavable linkage for use in a liposome | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2005-12-08 | — | — | US | disclosed |
| EP-1579874-A2 | Conjugate having a cleavable linkage for use in a liposome | ALZA Corporation (US) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004110497-A2 | MITOMYCIN CONJUGATES CLEAVABLE BY THIOLS | ALZA CORPORATION (US) | 2004-12-23 | — | — | WO | disclosed |
| US-20040161455-A1 | Method for treating multi-drug resistant tumors | ALZA CORPORATION | 2004-08-19 | — | — | US | disclosed |
| US-20030054028-A1 | Conjugate having a cleavable linkage for use in a liposome | ALZA CORPORATION | 2003-03-20 | — | — | US | disclosed |
| US-6365179-B1 | CONJUGATE FOR USE IN LIPOSOMAL DRUG-DELIVERY VEHICLE INCLUDING HYDROPHOBIC MOIETY SUITABLE FOR INCORPORATION INTO LIPOSOMAL LIPID BILAYER AND THERAPEUTIC DRUG COVALENTLY ATTACHED TO DITHIOBENZYL MOIETY IN ORTHO OR PARA POSITION | ALZA CORPORATION | 2002-04-02 | — | — | US | disclosed |
| EP-1173222-A2 | CONJUGATE HAVING A CLEAVABLE LINKAGE FOR USE IN A LIPOSOME | ALZA CORPORATION (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000064484-A2 | CONJUGATE HAVING A CLEAVABLE LINKAGE FOR USE IN A LIPOSOME | ALZA CORPORATION (US) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050271715-A1 | Conjugate having a cleavable linkage for use in a liposome | LANCL1, LIPA, LYPLA2 | IDO1 2387/4885MEN1 2460/4885KMT2A 2998/4885 |
| US-20040161455-A1 | Method for treating multi-drug resistant tumors | CYP11A1, MGST3, ME3 | IDO1 1621/4885MEN1 561/4885KMT2A 2158/4885 |
| US-20030054028-A1 | Conjugate having a cleavable linkage for use in a liposome | LANCL1, LIPA, LYPLA2 | IDO1 2387/4885MEN1 2460/4885KMT2A 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.